ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,510 | +1108.0% | 72,455 | +1284.6% | 0.02% | +1600.0% |
| Q2 2023 | $125 | -95.6% | 5,233 | -96.6% | 0.00% | -97.0% |
| Q1 2023 | $2,860 | +1176.8% | 151,978 | +981.4% | 0.03% | +1000.0% |
| Q4 2022 | $224 | -99.9% | 14,054 | -41.3% | 0.00% | -40.0% |
| Q3 2022 | $392,000 | -61.1% | 23,945 | -66.5% | 0.01% | -54.5% |
| Q2 2022 | $1,007,000 | +541.4% | 71,499 | +1000.7% | 0.01% | +1000.0% |
| Q1 2022 | $157,000 | -73.2% | 6,496 | -74.1% | 0.00% | -66.7% |
| Q4 2021 | $586,000 | -42.8% | 25,119 | -59.3% | 0.00% | -40.0% |
| Q3 2021 | $1,024,000 | +185.2% | 61,655 | +319.2% | 0.01% | +150.0% |
| Q2 2021 | $359,000 | +81.3% | 14,708 | +91.4% | 0.00% | +100.0% |
| Q1 2021 | $198,000 | -26.4% | 7,684 | +52.5% | 0.00% | 0.0% |
| Q4 2020 | $269,000 | -23.1% | 5,038 | -40.6% | 0.00% | -50.0% |
| Q3 2020 | $350,000 | -11.6% | 8,485 | +3.9% | 0.00% | -33.3% |
| Q2 2020 | $396,000 | -66.0% | 8,168 | -70.4% | 0.00% | -72.7% |
| Q1 2020 | $1,165,000 | +27.3% | 27,573 | +28.9% | 0.01% | +37.5% |
| Q4 2019 | $915,000 | +13.0% | 21,384 | -5.0% | 0.01% | +14.3% |
| Q3 2019 | $810,000 | +313.3% | 22,507 | +207.3% | 0.01% | +600.0% |
| Q2 2019 | $196,000 | -30.7% | 7,324 | -30.6% | 0.00% | -66.7% |
| Q1 2019 | $283,000 | +11.4% | 10,550 | -32.9% | 0.00% | +50.0% |
| Q4 2018 | $254,000 | -12.4% | 15,721 | +12.5% | 0.00% | 0.0% |
| Q3 2018 | $290,000 | +100.0% | 13,971 | +47.5% | 0.00% | +100.0% |
| Q2 2018 | $145,000 | -77.9% | 9,473 | -67.5% | 0.00% | -80.0% |
| Q1 2018 | $656,000 | -65.9% | 29,179 | -54.4% | 0.01% | -72.2% |
| Q4 2017 | $1,925,000 | +1073.8% | 63,934 | +1371.1% | 0.02% | +1700.0% |
| Q3 2017 | $164,000 | -18.8% | 4,346 | -39.9% | 0.00% | -50.0% |
| Q2 2017 | $202,000 | -47.8% | 7,235 | -35.7% | 0.00% | -33.3% |
| Q1 2017 | $387,000 | -79.9% | 11,249 | -83.2% | 0.00% | -81.2% |
| Q4 2016 | $1,927,000 | +363.2% | 66,804 | +410.9% | 0.02% | +300.0% |
| Q3 2016 | $416,000 | +2.5% | 13,077 | +4.6% | 0.00% | +33.3% |
| Q2 2016 | $406,000 | +28.5% | 12,502 | +10.8% | 0.00% | +50.0% |
| Q1 2016 | $316,000 | -7.6% | 11,288 | +17.5% | 0.00% | 0.0% |
| Q4 2015 | $342,000 | -43.0% | 9,607 | -47.0% | 0.00% | -50.0% |
| Q3 2015 | $600,000 | +174.0% | 18,133 | +246.8% | 0.00% | +300.0% |
| Q2 2015 | $219,000 | -31.6% | 5,228 | -46.8% | 0.00% | -50.0% |
| Q1 2015 | $320,000 | -61.2% | 9,820 | -62.2% | 0.00% | -50.0% |
| Q4 2014 | $824,000 | +127.0% | 25,966 | +77.0% | 0.00% | +100.0% |
| Q3 2014 | $363,000 | +55.8% | 14,670 | +42.2% | 0.00% | +100.0% |
| Q2 2014 | $233,000 | +91.0% | 10,318 | +106.4% | 0.00% | 0.0% |
| Q1 2014 | $122,000 | -69.3% | 5,000 | -65.4% | 0.00% | -50.0% |
| Q3 2013 | $397,000 | – | 14,440 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |